- Home
- NFGC vs MDXG Comparison
NFGC vs MDXG Comparison
Compare NFGC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NFGC | MDXG |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NFGC | MDXG |
|---|---|---|
| Price | $2.84 | $4.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 03-20-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | $1,903.79 | N/A |
| P/E Ratio | ★ N/A | $18.40 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $0.93 | $4.89 |
| 52 Week High | $3.59 | $8.75 |
Technical Indicators
Market Signals| Indicator | NFGC | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 20.38 |
| Support Level | $3.21 | $4.89 |
| Resistance Level | $3.59 | $5.23 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 21.84 | 9.39 |
Price Performance
Historical ComparisonAbout NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.